Harrow (HROW) Stock Price
Harrow Price
Harrow (HROW) Stock | ISIN US4158581094 | WKN A2PBJD. The current Harrow stock price is 41.5 USD (2026). Revenue is 361.88 M USD. Net income is 50.9 M USD. The P/E ratio is 29.97. Market capitalization is 1.53 B USD. Harrow operates in the Health sector.
Over the last 13 years Harrow grew revenue by 83.8% annually, reaching 272.3 M USD. For Harrow, the net margin of -1.9% is up versus -25.5% a few years ago.
Harrow stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Harrow over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Harrow stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Harrow's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Harrow Price |
|---|
Harrow Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Harrow Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (B USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|
| 0.13 | 0.2 | 0.27 | 0.36 | 0.54 | 0.74 | 1.03 | 1.18 |
| 47.73 | 53.08 | 36.68 | 32.72 | 48.75 | 37.99 | 39.41 | 14.62 |
| 69.23 | 75.38 | 75 | 56.51 | 37.99 | 27.53 | 19.75 | 17.23 |
| 90 | 150 | 204 | 204 | 204 | 204 | 204 | 204 |
| -24 | -17 | -5 | 50 | 107 | 186 | 217 | 233 |
| 71.43 | -29.17 | -70.59 | -1,100 | 114 | 73.83 | 16.67 | 7.37 |
| 32.62 | 35.65 | 36.76 | 36.76 | 36.76 | 36.76 | 36.76 | 36.76 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Harrow generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Harrow retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Harrow's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Harrow has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Harrow's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Harrow stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Harrow Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Harrow business model & stock analysis
Harrow SWOT Analysis
Strengths
Harrow Health Inc possesses several strengths, which contribute to its competitive advantage in the market. These strengths include:
- Strong brand reputation and recognition in the healthcare industry.
- Robust portfolio of high-quality pharmaceutical products.
- Effective distribution network ensuring wide market reach.
- Strong relationships with healthcare professionals and key stakeholders.
- Commitment to innovation and research to drive product development.
Weaknesses
Although Harrow Health Inc has demonstrated strengths, it also faces certain weaknesses, which need to be addressed for sustained growth. These weaknesses include:
- Relatively high dependence on a limited number of major customers.
- Inadequate geographical diversification leading to vulnerability in certain markets.
- Higher production costs compared to some competitors.
- Limited market share in specific therapeutic areas.
Opportunities
Harrow Health Inc can capitalize on various opportunities to expand its market presence and enhance profitability. These opportunities are:
- Increasing demand for specialized pharmaceutical products.
- Growing healthcare expenditure and favorable regulatory environment.
- Potential for strategic partnerships or acquisitions to broaden product offerings.
- Emerging markets providing untapped growth potential.
Threats
Harrow Health Inc must also be aware of potential threats that could hinder its progress. These threats include:
- Intense competition within the pharmaceutical industry.
- Changing industry regulations and compliance requirements.
- Risks associated with product safety and recalls.
- Economic fluctuations and healthcare cost containment measures.
Harrow Segments
Harrow Revenue by Segment (1/4)
Max
Details
Harrow Revenue by Segment (2/4)
Max
Details
Harrow Revenue by Segment (3/4)
Max
Details
Harrow Revenue by Segment (4/4)
Max
Details
Harrow Eulerpool Fair Value
Harrow historical P/E ratio, EBIT multiple, and P/S ratio
Harrow annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Harrow shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Harrow Earnings Estimates
Harrow Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/11/2026 | -0.41USD | 53.47 MUSD | 2026 Q1 |
| 5/7/2026 | -0.41USD | 53.47 MUSD | 2026 Q1 |
| 5/6/2026 | -0.41USD | 53.47 MUSD | 2026 Q1 |
| 3/2/2026 | 0.38USD | 90.22 MUSD | 2025 Q4 |
| 8/11/2025 | 0.01USD | 67.32 MUSD | 2025 Q2 |
| 11/13/2024 | -0.05USD | 53.87 MUSD | 2024 Q3 |
| 11/11/2024 | -0.05USD | 53.87 MUSD | 2024 Q3 |
| 5/9/2024 | -0.01USD | 43.49 MUSD | 2024 Q1 |
| 3/21/2024 | -0.05USD | 38.61 MUSD | 2023 Q4 |
| 11/13/2023 | 0.06USD | 29.28 MUSD | 2023 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Harrow stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Harrow shareholder structure
| % | Name |
|---|---|
10.56841% | |
8.1232% | |
6.10483% | |
5.20618% | |
5.01378% | |
4.58216% | |
2.496% | |
2.20666% | |
2.13569% | |
2.13202% |
Harrow Executives and Management Board
Mr. Mark Baum
(52)Chairman of the Board, Chief Executive Officer · since 2011
Mr. Andrew Boll
(42)President, Chief Financial Officer, Company Secretary
Dr. Adrienne Graves
(71)Independent Director
Mrs. Lauren Silvernail
(67)Independent Director
Mr. Perry Sternberg
(56)Lead Independent Director
Harrow Supply Chain
Frequently asked questions about Harrow
Harrow Health Inc is a pharmaceutical company that operates on a unique business model. They specialize in acquiring and commercializing branded prescription drugs. By acquiring smaller pharmaceutical companies and their products, Harrow Health Inc focuses on improving patient access to vital medications. Their business strategy involves developing partnerships, managing intellectual property, and conducting research to ensure the availability of necessary medications. Through this model, Harrow Health Inc aims to address unmet medical needs and offer innovative solutions to patients. This approach enables the company to play a significant role in the pharmaceutical industry and deliver impactful healthcare products.
Harrow stock
Harrow Peer Group
Harrow Ticker
Harrow FIGI
All fundamentals and in-depth analysis of Harrow
Our stock analysis for Harrow Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Harrow Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.